Thrace Health Limited Filleted accounts for Companies House (small and micro)

THRACE HEALTH LIMITED - Company Information

0 false false false false false false false false false true false false false false false false No description of principal activity 2022-06-01 Sage Accounts Production Advanced 2021 - FRS102_2021 xbrli:pure xbrli:shares iso4217:GBP 08090134 2022-06-01 2023-05-31 08090134 2023-05-31 08090134 2022-05-31 08090134 bus:Director1 2022-06-01 2023-05-31 08090134 core:WithinOneYear 2023-05-31 08090134 core:WithinOneYear 2022-05-31 08090134 core:ShareCapital 2023-05-31 08090134 core:ShareCapital 2022-05-31 08090134 core:RetainedEarningsAccumulatedLosses 2023-05-31 08090134 core:RetainedEarningsAccumulatedLosses 2022-05-31 08090134 bus:SmallEntities 2022-06-01 2023-05-31 08090134 bus:AuditExemptWithAccountantsReport 2022-06-01 2023-05-31 08090134 bus:AbridgedAccounts 2022-06-01 2023-05-31 08090134 bus:SmallCompaniesRegimeForAccounts 2022-06-01 2023-05-31 08090134 bus:PrivateLimitedCompanyLtd 2022-06-01 2023-05-31

COMPANY REGISTRATION NUMBER: 08090134

Thrace Health Limited

Filleted Unaudited Abridged Financial Statements

31 May 2023

Thrace Health Limited

Abridged Financial Statements

Year ended 31 May 2023

Contents	Page

Abridged statement of financial position	1

Notes to the abridged financial statements	2

Thrace Health Limited

Abridged Statement of Financial Position

31 May 2023

	2023		2022
Note	£	£	£
Creditors: amounts falling due within one year	14,797		14,797
	--------		--------
Net current liabilities		14,797	14,797
		--------	--------
Total assets less current liabilities		( 14,797)	( 14,797)
		--------	--------

Capital and reserves

Called up share capital	100	100
Profit and loss account	( 14,897)	( 14,897)
	--------	--------
Shareholders deficit	( 14,797)	( 14,797)
	--------	--------

These abridged financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A of FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.

In accordance with section 444 of the Companies Act 2006, the abridged statement of income and retained earnings has not been delivered.

For the year ending 31 May 2023 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

- The members have not required the company to obtain an audit of its abridged financial statements for the year in question in accordance with section 476 ;

- The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of abridged financial statements .

All of the members have consented to the preparation of the abridged statement of income and retained earnings and the abridged statement of financial position for the year ending 31 May 2023 in accordance with Section 444(2A) of the Companies Act 2006.

These abridged financial statements were approved by the board of directors and authorised for issue on 29 July 2023 , and are signed on behalf of the board by:

Mr Kadoglou
Director

Company registration number: 08090134

Thrace Health Limited

Notes to the Abridged Financial Statements

Year ended 31 May 2023

1. General information

The company is a private company limited by shares, registered in England and Wales. The address of the registered office is 151 Askew Road, London, W12 9AU.

2. Statement of compliance

These abridged financial statements have been prepared in compliance with Section 1A of FRS 102, 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland'.

3. Accounting policies

Basis of preparation

The abridged financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.

The abridged financial statements are prepared in sterling, which is the functional currency of the entity.

Financial instruments

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the entity after deducting all of its financial liabilities. Where the contractual obligations of financial instruments (including share capital) are equivalent to a similar debt instrument, those financial instruments are classed as financial liabilities. Financial liabilities are presented as such in the balance sheet. Finance costs and gains or losses relating to financial liabilities are included in the profit and loss account. Finance costs are calculated so as to produce a constant rate of return on the outstanding liability. Where the contractual terms of share capital do not have any terms meeting the definition of a financial liability then this is classed as an equity instrument. Dividends and distributions relating to equity instruments are debited direct to equity.

4. Director's advances, credits and guarantees

Ath the year end the company owed to the director £14,797 (2022: £14,797)

5. Related party transactions

The company was under the control of Mr N Kadoglou throughout the current and previous year. Mr Kadoglou is the managing director and majority shareholder. No transactions with related parties were undertaken such as are required to be disclosed under FRSSE8.